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Jang-Soo Chun1 and Je-Hwang Ryu3,4*Abstract
Introduction: Wnt ligands bind to low-density lipoprotein receptor–related protein (LRP) 5 or 6, triggering a cascade
of downstream events that include β-catenin signaling. Here we explored the roles of LRP5 in interleukin 1β (IL-1β)- or
Wnt-mediated osteoarthritic (OA) cartilage destruction in mice.
Methods: The expression levels of LRP5, type II collagen, and catabolic factors were determined in mouse articular
chondrocytes, human OA cartilage, and mouse experimental OA cartilage. Experimental OA in wild-type, Lrp5 total
knockout (Lrp5−/−) and chondrocyte-specific knockout (Lrp5fl/fl;Col2a1-cre) mice was caused by aging, destabilization of
the medial meniscus (DMM), or intra-articular injection of collagenase. The role of LRP5 was confirmed in vitro by small
interfering RNA–mediated knockdown of Lrp5 or in Lrp5−/− cells treated with IL-1β or Wnt proteins.
Results: IL-1β treatment increased the expression of LRP5 (but not LRP6) via JNK and NF-κB signaling. LRP5 was
upregulated in human and mouse OA cartilage, and Lrp5 deficiency in mice inhibited cartilage destruction. Treatment
with IL-1β or Wnt decreased the level of Col2a1 and increased those of Mmp3 or Mmp13, whereas Lrp5 knockdown
ameliorated these effects. In addition, we found that the functions of LRP5 in arthritic cartilage were subject to
transcriptional activation by β-catenin. Moreover, Lrp5−/− and Lrp5fl/fl;Col2a1-cre mice exhibited decreased cartilage
destruction (and related changes in gene expression) in response to experimental OA.
Conclusions: Our findings indicate that LRP5 (but not LRP6) plays an essential role in Wnt/β-catenin-signaling-mediated
OA cartilage destruction in part by regulating the expression levels of type II collagen, MMP3, and MMP13.Introduction
Osteoarthritis (OA), which is the most common chronic
degenerative joint disorder worldwide, is characterized
primarily by cartilage degradation and narrowing of the
joint spaces [1]. Both genetic and acquired factors, such as
obesity, mechanical influences and age, are involved in the
complex pathogenesis of OA, whereby cartilage homeo-
stasis is disrupted by biophysical factors (for example,
mechanical stress) and biochemical factors (for example,* Correspondence: jesryu@jnu.ac.kr
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unless otherwise stated.proinflammatory cytokines). The chondrocyte is a unique
resident cell that synthesizes cartilage-specific extracellular
matrix (ECM) components as well as various catabolic and
anabolic factors. The pathogenesis of OA activates various
biochemical pathways in chondrocytes, leading to proin-
flammatory cytokine production, inflammation, degradation
of the ECM by matrix metalloproteinases (MMPs) and a
disintegrin and metalloproteinase with thrombospondin
motifs (ADAMTS), and cessation of ECM synthesis via the
dedifferentiation and apoptosis of chondrocytes [2,3]. How-
ever, the molecular mechanisms underlying OA are not yet
fully understood. The elucidation of such mechanisms
could facilitate the development of new and effective thera-
peutic targets for the treatment of OA.
The Wnt signaling pathway is involved in cartilage de-
velopment and homeostasis, as evidenced by the fact that
a number of Wnt proteins and Frizzled (Fz) receptors ared. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of arthritic cartilage [5]. Interestingly, both chondrocyte-
specific conditional activation and selective inhibition of
β-catenin in mice have been shown to yield OA-like
phenotypes, albeit via different mechanisms [6,7]. Several
additional lines of evidence link Wnt/β-catenin signaling
with OA, further supporting the notion that the Wnt/
β-catenin pathway plays a role in the pathophysiology of
cartilage [8-10].
Low-density lipoprotein receptor-related protein 5
(LRP5), which, together with LRP6, forms a distinct
subfamily of LRPs), is a coreceptor for Wnt ligands,
whereby the interaction of LRP5 with Axin initiates Wnt
signaling by binding to members of the Fz receptor
family [11]. LRP5 is one of the most intensively studied
regulators of bone remodeling, largely because Lrp5
loss-of-function mutations cause the autosomal recessive
human disorder osteoporosis-pseudoglioma syndrome
(OPPG) [12], whereas activating mutations in Lrp5 cause
high bone mass syndrome [13]. Lrp6-deficient mice
display phenotypes similar to those seen in several Wnt
knockouts (KOs) and die between embryonic day 14.5
and birth [14]. Despite the clear association of LRP5
with Wnt signaling and the involvement of Wnt/β-
catenin signaling in cartilage degeneration, however,
relatively few researchers have reported the involvement
of LRP5 in OA pathogenesis. The OA susceptibility
locus on chromosome 11q12-13 is in close proximity to
the Lrp5 gene, and a single polymorphism in Lrp5 can
confer increased risk for spinal OA and osteophyte
formation [15]. LRP5 expression is increased in articular
cartilage from OA patients and has been linked to
increased MMP13 expression in chondrocytes [16].
Furthermore, bone morphogenetic protein 2–induced
activation of Wnt/β-catenin signaling, which has been
linked to enhanced catabolic activity of LRP5, contri-
butes to hypertrophy in OA chondrocytes [17]. However,
in a recent study, investigators reported that LRP5 defi-
ciency could increase (rather than decrease) cartilage
degradation in instability-induced OA [18]. Given this
apparent discrepancy, additional work is clearly war-
ranted to elucidate the molecular mechanisms under-
lying the LRP5-mediated regulation of OA pathogenesis.
In our present study, we investigated the distinct ex-
pression patterns of LRP5 and LRP6 in OA cartilage, elu-
cidated the catabolic regulation of LRP5 in experimental
OA using total and chondrocyte-specific conditional KO
mice and examined the mechanisms underlying the
LRP5-induced modulation of Wnt/β-catenin signaling.
Our findings indicate that LRP5 (but not LRP6) plays an
essential role in Wnt/β-catenin signaling–mediated OA
cartilage destruction by upregulating catabolic factors (for
example, MMP3 and MMP13) and downregulating the
anabolic factor type II collagen.Methods
Mice
Imprinting control region (ICR) mice were used for the
chondrogenesis studies, and male C57BL/6, Lrp5−/−,
Lrp5fl/fl;Col2a1-cre [19], STR/ort and CBA/CaCrl mice
were used for the experimental OA studies. The Lrp5−/−
and Lrp5fl/fl mice targeting exons 6 through 8 of Lrp5
(kindly provided by Dr Gerard Karsenty of Columbia
University (New York, NY, USA) [20]) were backcrossed
against the C57BL/6J strain for eight generations. The
Col2a1-cre-transgenic mice were obtained from The
Jackson Laboratory (Bar Harbor, ME, USA) and back-
crossed with Lrp5fl/fl mice to generate chondrocyte-
specific conditional KO mice (Lrp5fl/fl;Col2a1-cre). The
genotyping primers for Lrp5−/−, Lrp5fl/fl and Col2a1-cre
were the same as those described previously [20]. The
STR/ort and CBA/CaCrl mice were obtained from
Harlan Laboratories (Indianapolis, IN, USA). All proto-
cols were reviewed and approved by the Institutional
Animal Care and Use Committee of Chonnam National
University.
Human arthritic cartilage and experimental osteoarthritis
Human OA cartilage was sourced from individuals under-
going arthroplasty [21]. Human cartilage was kindly pro-
vided by Dr Churl-Hong Chun of Wonkwang University
(Iksan, Republic of Korea). The Institutional Review Board
of the Wonkwang University Hospital approved the use
of these materials, and all individuals provided written
informed consent to be donors before undergoing surgery.
Spontaneous OA in STR/ort mice [22] was examined at
28 weeks of age, with CBA/CaCrl mice used as controls.
Aging studies were performed in 12-month-old mice, and
experimental OA was induced in mice by destabilization
of the medial meniscus (DMM) surgery [23] or by intra-
articular injection of collagenase in 8-week-old male mice
[24] and in in Lrp5−/− mice and their wild-type (WT) lit-
termates. Sham-operated and phosphate buffered saline–
injected mice were used as controls for the DMM and
collagenase-injected models, respectively. Mice were ana-
lyzed at 8 weeks after DMM surgery or 4 weeks after col-
lagenase injection.
Micromass culture and primary culture of articular
chondrocytes
Mesenchymal cells were derived from the limb buds of
ICR mouse embryos 11.5 days postcoitus and main-
tained as micromass cultures for induction of chondro-
genesis as described previously [8]. Mouse articular
chondrocytes were isolated from knee cartilage obtained
from postnatal day 5 mice [25]. The articular cartilage
was preincubated for 2 hours at 37°C with 0.2% trypsin
and 0.2% type II collagenase and further digested with
0.2% type II collagenase for 90 minutes. On culture day
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(IL-1β) (Calbiochem, San Diego, CA, USA), Wnt3a or
Wnt7a (R&D Systems, Minneapolis, MN, USA) for
24 hours. Apoptosis was induced by treatment with an
anti-Fas antibody (BD Biosciences, San Jose, CA, USA).
Briefly, chondrocytes from articular cartilage of WT or
Lrp5−/− mice were incubated in the presence or absence
of IL-1β (1 ng/ml) for 24 hours, then exposed to the
anti-Fas antibody and recombinant protein G for an
additional 6 hours. Hamster immunoglobulin G2 was
used as a control. The cells were stained with fluorescein
isothiocyanate–conjugated annexin V (BD Biosciences),
and apoptotic chondrocytes were quantified by fluo-
rescence-activated cell sorting analysis.
Immunofluorescence microscopy and
immunohistochemistry
Chondrocytes were cultured on glass coverslips, fixed with
3.5% paraformaldehyde and permeabilized with 0.1%
Triton X-100. The cells were incubated for 1 hour with an
antibody against type II collagen followed by incubation
for 1 hour with an Alexa 488–conjugated secondary anti-
body (Invitrogen, Carlsbad, CA, USA). Ectopic expression
of LRP5 was determined by labeling with an anti-LRP5
antibody and an Alexa 555–conjugated secondary anti-
body (Invitrogen). Apoptosis of chondrocytes in cartilage
tissue was determined by terminal deoxynucleotidyl
transferase deoxyuridine triphosphate nick end labeling
(TUNEL) staining using a kit purchased from Roche
Diagnostics (Indianapolis, IN, USA). Specimens were
visualized under an IX81 inverted fluorescence micro-
scope (Olympus America, Center Valley, PA, USA) driven
by MetaMorph imaging software (Molecular Devices,
Sunnyvale, CA, USA). Normal and OA human cartilage
samples were frozen, sectioned at a thickness of 6 μm and
subjected to Alcian blue and immunohistochemical stain-
ing. Mouse cartilage was fixed in 4% paraformaldehyde,
decalcified in 0.5 M ethylenediaminetetraacetic acid
(pH 7.4), embedded in paraffin and sectioned at a thick-
ness of 6 μm. Cartilage destruction was evaluated by
Safranin O staining and scored according to Mankin’s
method [26]. Immunostaining of LRP5, MMP3, MMP13
and β-catenin in human and mouse cartilage was per-
formed using standard techniques [21].
RT-PCR and quantitative RT-PCR
Total RNA isolated from mouse articular chondrocytes
and OA cartilage tissues was reverse-transcribed, and the
resulting cDNA was PCR-amplified. The PCR primers
and conditions used for mouse Col2a1, Mmp3, Mmp13,
Ptgs2, Nos2 and Gapdh were previously described [21].
The PCR primers for Lrp5 and Lrp6 were as follows:
mouse Lrp5, sense: 5′-CTGAGGAACGTCAAAGCCAT




CG-3′, and antisense: 5′-GGTGAAGACCAAGAAGG CC
TCAGG-3′; and human LRP6, sense: 5′-ATTGTAGTTG
GAG GCTTGGAGGATGC-3′, and antisense 5′-CCATC
CATTCCAGCACGTTCTATC-3′. Quantitative RT-PCR
(qRT-PCR) was performed using an iCycler (Bio-Rad
Laboratories, Hercules, CA, USA) and SYBR Premix Ex
Taq (Tli RNaseH Plus) (TaKaRa Bio, Kyoto, Japan).
Western blot analysis
Total cell lysates were prepared with lysis buffer (pH 7.4)
containing 150 mM NaCl, 1% Nonidet P-40, 50 mM Tris,
0.2% SDS, 5 mM NaF, a protease inhibitor cocktail and a
phosphatase inhibitor cocktail. Proteins were resolved by
SDS-PAGE, transferred to nitrocellulose membranes, de-
tected by incubation with the appropriate primary antibody
and a peroxidase-conjugated secondary antibody (Sigma-
Aldrich, St Louis, MO, USA) and visualized using an
enhanced chemiluminescence system (GE Healthcare Life
Sciences, Pittsburgh, PA, USA). The primary antibodies
used were purchased from ABGENT (LRP5, AP6157a;
San Diego, CA, USA), EMD Millipore (type II collagen,
MAB8887; Billerica, MA, USA), BD Biosciences (extra-
cellular signal-regulated kinase (ERK), 610408; β-catenin,
610154), Santa Cruz Biotechnology (inhibitor of nuclear
factor κB α, SC-371; and p38, SC-535; Santa Cruz, CA,
USA) and Cell Signaling Technology (phosphorylated ERK,
9101; pp38, 9216; c-Jun N-terminal kinase (JNK), 9252; and
phosphorylated JNK, 9255; Danvers, MA, USA).
Transfection and reporter gene assay
Mouse articular chondrocytes were cultured for 3 days,
transfected for 4 hours with Lrp5 small interfering RNA
(siRNA) (Dharmacon, Lafayette, CO, USA) or pSPORT6-
Lrp5 (Open Biosystems, Huntsville, AL, USA) using
Lipofectamine 2000 reagent (Invitrogen), then treated with
IL-1β, Wnt3a or Wnt7a. A nonsilencing control siRNA and
empty vector were used as the negative controls. To deter-
mine the transcriptional activity of β-catenin-Tcf/Lef, we
used a reporter gene assay. Chondrocytes were transfected
with 1 μg of reporter gene (TOPflash) or control gene
(FOPflash) (both from Upstate Biotechnology, Lake Placid,
NY, USA) and 1 μg of pCMV-β-galactosidase using
Lipofectamine 2000. The transfected cells were treated with
IL-1β, Wnt3a or Wnt7a for 24 hours, then luciferase acti-
vity was measured and normalized with respect to transfec-
tion efficiency (as measured by β-galactosidase activity).
Statistical analysis
The nonparametric Mann–Whitney U test was used to
analyze data based on ordinal grading systems, such as
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scores. For qRT-PCR results and apoptotic cell numbers,
the data were first tested for conformation to a normal
distribution using the Shapiro-Wilk test, then analyzed by
Student’s t-test (pairwise comparisons) or analysis of
variance with post hoc tests (multiple comparisons) as ap-
propriate. Significance was accepted at the 0.05 level of
probability (P < 0.05).
Results
Lrp5 (but not Lrp6) is upregulated via JNK and NF-κB
pathways during IL-1β-mediated pathogenesis of
chondrocytes
We first examined the expression levels of Lrp5 and
Lrp6 during the chondrogenic differentiation of mesen-
chymal cells obtained from mouse embryonic limb buds
and subjected to micromass culture. We found that
Col2a1 (which encodes the chondrocyte marker type II
collagen) peaked on day 6 of micromass culture, Lrp6
expression decreased beginning on day 6 and Lrp5
expression was constant during chondrocyte differen-
tiation (Figure 1A). The basal levels of Lrp5 and Lrp6
mRNA were very low in mouse articular chondrocytes.Figure 1 Upregulation of LRP5 in interleukin 1β-treated mouse articu
maintained as micromass cultures for 12 days, and the expression levels of Co
expression was confirmed by Western blot analysis. (B) and (C) Primary cultur
concentrations of interleukin 1β (IL-1β) for 24 hours (B) or with 1 ng/ml IL-1β
Western blot analysis were carried out. Values are presented as means ± SEM
(G) RT-PCR and Western blot analysis were performed on chondrocytes treate
inhibitors (micromolar concentrations): PD98059, an extracellular signal-regula
(MAP) kinase inhibitor (E); SP600125, a c-Jun N-terminal kinase (JNK) inhibitor
(BAY11-7085), an inhibitor of nuclear factor κB α (IκBα) (G).In pathogenic primary culture chondrocytes treated with
IL-1β (the primary inflammatory cytokine involved in car-
tilage destruction), however, Lrp5 expression was drama-
tically increased in a dose-dependent manner (Figure 1B)
and a time-dependent manner (Figure 1C), whereas Lrp6
expression was constant (Figures 1B and 1C). Consistent
with our previous observations [20], IL-1β treatment
increased the levels of Mmp13 while abrogating Col2a1
expression. Our qRT-PCR analysis revealed that IL-1β
treatment triggered an approximately tenfold increase of
Lrp5 expression, but had no effect on Lrp6 expression
(Figures 1B and 1C). IL-1β treatment of chondrocytes
triggered the activation of nuclear factor κB (NF-κB) and
various mitogen-activated protein (MAP) kinase subtypes,
including ERK, p38 kinase and JNK. Inhibition of ERK or
p38 kinase had no effect on LRP5 expression (Figures 1D
and 1E), but the blockade of JNK or NF-κB signaling (with
SP600125 or BAY11-7085, respectively) markedly inhi-
bited the IL-1β-induced increase in LRP5 expression
(Figures 1F and 1G). These data indicate that LRP5 (but
not LRP6) is increased during IL-1β-induced chondrocyte
dedifferentiation and that this upregulation of LRP5 is
mediated via the JNK and NF-κB signaling pathways.lar chondrocytes. (A) Mesenchymal cells from mouse embryos were
l2a1, Mmp13, Lrp5, Lrp6 and Gapdh were detected by RT-PCR. LRP5
ed mouse articular chondrocytes were treated with the indicated
for the indicated periods (C), and RT-PCR, quantitative RT-PCR and
(*P < 0.001, **P < 0.0001; n = 6 independent experiments). (D) through
d with IL-1β (1 ng/ml) for 24 hours in the presence of the indicated
ted kinase (ERK) inhibitor (D); SB203580, a p38 mitogen-activated protein
(F); and (2E)-3-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-2-propenenitrile
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osteoarthritic cartilage
Because Lrp5 expression was distinctly regulated during
IL-1β-induced chondrocyte dedifferentiation, we examined
whether LRP5 plays a role in OA cartilage destruction
in vivo. We initially examined LRP5 levels in OA-affected
human cartilage obtained from individuals who had under-
gone arthroplasty. The degree of cartilage damage in the
human OA samples was ICRS grade 4 as confirmed by
Alcian blue staining (Figure 2A). In these samples, LRP5
was significantly expressed in OA-affected human cartilage
but barely detectable in normal cartilage (Figure 2A). This
upregulation of Lrp5 mRNA in human OA cartilage was
confirmed by RT-PCR and qRT-PCR analyses (Figure 2A).
We also found that the protein and mRNA levels of LRP5
were increased in cartilage from STR/ort mice (which were
genetically predisposed to develop OA-like lesions in their
medial tibial cartilage at age 6 months [21]) compared with
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Figure 2 LRP5 is upregulated in human and mouse experimental oste
(osteoarthritis (OA)) human OA cartilage were examined with Alcian blue stai
assessed, and a typical result is presented. The mRNA levels of Lrp5 and Lrp6 i
measured by quantitative RT-PCR (qRT-PCR). (B) through (D) Safranin O staini
from STR/ort (STR) OA mice and control CBA/CaCrl (CBA) mice (n = 8) (B); C57
phosphate-buffered saline (n = 6) (C); and C57BL/6 mice subjected to sham o
and Lrp6 mRNA levels were examined by RT-PCR and quantified by qRT-PCR
Cartilage Repair Society (ICRS) grade for human cartilage samples (A) and by M
means ± SEM (*P < 0.01, **P < 0.001; n > 7). Scale bar: 50 μm.also observed increased LRP5 expression in mouse OA
cartilage following collagenase injection (Figure 2C) and
DMM surgery (Figure 2D). Thus, LRP5 expression was
significantly elevated in all human and mouse OA cartilage
samples examined in the present study.
Catabolism-promoting gene regulation by LRP5 in
dedifferentiated chondrocytes
Because the above-described results suggest that LRP5
may negatively regulate cartilage maintenance, we investi-
gated the effects of LRP5 on catabolic and anabolic gene
expression levels in chondrocytes. Ectopic expression of
LRP5 significantly suppressed type II collagen expression
at the transcript and protein levels (Figure 3A, left) but
had no effect on the expression levels of catabolic genes
such as Mmp3, Mmp13, Adamts4, Adamts5 and Ptgs2
(data not shown). Our qRT-PCR analysis clearly revealed
that type II collagen expression was dose-dependently
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oarthritic cartilage. (A) Undamaged (Normal/Nor) and damaged
ning and immunostaining for LRP5. Six patients were independently
n undamaged and damaged OA cartilage were examined by RT-PCR and
ng and immunostaining for LRP5 were performed on cartilage samples
BL/6 mice after intra-articular injection of collagenase (Coll) or control
r destabilization of the medial meniscus (DMM) surgery (n = 10) (D). Lrp5
(B) through (D). Cartilage destruction was evaluated by International
ankin score for mouse cartilage (B) through (D). Values are presented as
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articular chondrocyte cultures transfected with pSPORT-
Lrp5 indicated that cells highly expressing LRP5 were
negative for type II collagen staining (Figure 3B). These
data suggest that LRP5 expression was sufficient to cause
chondrocyte dedifferentiation in our experimental system.
Consistent with the unaltered expression of Lrp6 in vitro,
however, LRP6 was barely detected in human and mouse
OA cartilage samples, and LRP6 overexpression did not
alter the expression levels of the tested genes (data not
shown).
Next, we examined the effects of siRNA-mediated
knockdown of Lrp5 in dedifferentiated chondrocytes. IL-1β
is known to trigger the expression of various catabolic fac-
tors (for example, MMP1, MMP3, MMP9, MMP12,
MMP13, ADAMTS4, ADAMTS5, nitric oxide synthase 2
and prostaglandin-endoperoxide synthase 2) in primary
cultures of articular chondrocytes [20]. Accordingly,
we examined the possibility that LRP5 mediates the
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Figure 3 Ectopic expression of LRP5 regulates type II collagen expres
chondrocytes were transfected with empty vector (EV; 1 μg) or the indicate
expression in Lrp5-overexpressing chondrocytes was determined by RT-PCR
collagen and LRP5 were examined by Western blot analysis. Values are pre
cells; n = 8). (B) Articular chondrocytes cultured on glass coverslips were tra
against type II collagen and LRP5. Scale bar: 20 μm. (C) through (E) Chond
(C-si) or the indicated nanomolar concentrations of Lrp5 siRNA (Lrp5-si) and tr
mouse Wnt3a (D) or 500 ng/ml recombinant human Wnt7a (E). The mRNA e
Mmp13, Ptgs2 and Nos2) were assessed by RT-PCR.chondrocytes. siRNA-induced knockdown of Lrp5 was
found to block the IL-1β-induced upregulation of Mmp3
and Mmp13, as well as the IL-1β-induced downregulation
of Col2a1 (Figure 3C). To further confirm the effects of
LRP5 on Mmp3 and Mmp13 expression in dedifferentiated
chondrocytes, we stimulated the canonical Wnt pathway
with recombinant Wnt3a and Wnt7a proteins. Both
Wnt3a and Wnt7a induced chondrocyte dedifferentiation
by suppressing Col2a1 expression and concomitantly in-
creased Lrp5 expression (Figures 3D and 3E). However,
Wnt3a and Wnt7a had differential effects on MMP expres-
sion. Wnt3a triggered the induction of Mmp13 but not
Mmp3 (Figure 3D), whereas Wnt7a stimulated both
Mmp3 andMmp13 (Figure 3E).
Lrp5-knockout mice show inhibition of experimental
osteoarthritis-induced cartilage destruction
The specific in vivo functions of LRP5 were evaluated by
inducing experimental OA in Lrp5−/− mice via aging [21]
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sion in mouse articular chondrocytes. (A) Mouse articular
d amounts of pSPORT6-Lrp5 for 24 hours. Downregulation of Col2a1
and measured by quantitative RT-PCR. The protein levels of type II
sented as means ± SEM (*P < 0.05 and **P < 0.01 versus EV-transfected
nsfected with pSPORT6-Lrp5 and immunostained with antibodies
rocytes were transfected with 100 nM control small interfering RNA
eated with 1 ng/ml recombinant human IL-1β (C), 50 ng/ml recombinant
xpression levels of Lrp5, Col2a1 and various catabolic factors (Mmp3,
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WT mice subjected to aging (Figure 4A) or DMM surgery
(Figure 4B), whereas the degree of cartilage destruction
was markedly reduced in Lrp5−/− mice (Figures 4A and
4B). Consistent with our results following siRNA-media-
ted knockdown of Lrp5 (Figures 3C through 3E), the
IL-1β- or Wnt-mediated induction of Mmp3 and Mmp13
in articular chondrocytes obtained from LRP5−/− mice
were significantly decreased compared to those from their
corresponding WT littermates (Figures 4C through 4E).
To further determine whether the LRP5-mediated regula-
tion of Mmp3 and Mmp13 expression occurred via the
canonical Wnt/β-catenin signaling pathway, we examined
the effects of LiCl treatment, which inhibits glycogen
synthase kinase 3β (GSK3β). We found that LiCl treat-
ment of chondrocytes from WT mice further enhanced
the Wnt3a-mediated upregulation of Mmp13 and the
Wnt7a-mediated upregulation of Mmp3 and Mmp13,
whereas these parameters were unchanged in LiCl-treated
Lrp5−/− mice (Figures 4D and 4E).Figure 4 Lrp5-knockout inhibits aging-induced and destabilization of
(A) Spontaneous osteoarthritis (OA) in Lrp5-knockout (Lrp5-KO; Lrp5−/−) m
wild-type (WT) mice (n = 10 independent experimental animals). (B) Sham
meniscus (DMM) surgery in the right knee joint were performed in WT and Lr
and hematoxylin staining of cartilage sections and measured by Mankin score
presented immunostaining images of LRP5 in the knee articular cartilage are
(E) Chondrocytes obtained from WT and Lrp5−/− mice were treated with the
interleukin 1β (IL-1β) (C), Wnt3a (D) or Wnt7a (E), and the mRNA expression l
C: control, BSA: bovine serum albumin.LRP5 potentiates Wnt/β-catenin signaling during
osteoarthritis pathogenesis
Because GSK3β activity is primarily responsible for the
degradation of β-catenin, we next examined whether the
expression and/or activity levels of β-catenin could be reg-
ulated by LRP5. Ectopic expression of LRP5 in chondro-
cytes increased the transcriptional activation of β-catenin
as determined by a Tcf/Lef reporter gene assay using
TOPflash (containing an optimal Tcf/Lef-binding site) and
FOPflash (containing a mutated Tcf/Lef-binding site)
(Figure 5A). Treatment of chondrocytes from WT mice
with IL-1β, Wnt3a or Wnt7a also increased the transcrip-
tional activity of the β-catenin-Tcf/Lef complex, whereas
this activity was completely blocked in cells from Lrp5−/−
mice (Figure 5B). Consistent with these observations, the
expression levels of β-catenin and LRP5 were remarkably
increased in OA cartilage induced by DMM surgery, and
the β-catenin-expressing cells largely overlapped with the
LRP5-expressing cells (Figure 5C). Moreover, the ex-
pression levels of β-catenin and MMP13 were increased inthe medial meniscus–induced osteoarthritic cartilage destruction.
ice was examined at 12 months of age and compared with that in
operation in the left knee joint and destabilization of the medial
p5−/− mice (n = 20). Cartilage destruction was examined by Safranin O
. Values are expressed as means ± SEM (*P < 0.005). Scale bar: 50 μm. The
representative of at least seven independent tissue samples. (C) through
indicated concentrations (in nanograms per milliliter) of recombinant
evels of Lrp5, Col2a1, Mmp3 and Mmp13 were assessed by RT-PCR.
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cartilage (Figure 5D). Interestingly, the increases in
β-catenin, MMP3 and MMP13 found in the OA cartilage
of WT mice subjected to aging (Figure 5E) or DMM sur-
gery (Figure 5F) were not observed in experimental OA
cartilage samples from Lrp5−/− mice.
To control for unexpected effects from the lack of Lrp5
in noncartilage tissues, we generated chondrocyte-specific
conditional KO mice (Lrp5fl/fl;Col2a1-cre), whereby the
cre recombinase gene specifically deleted the Lrp5 gene
from cartilage, but not other tissues, such as brain, heart
and bone (Figure 6A). Lrp5fl/fl;Col2a1-cre and correspon-
ding Lrp5fl/fl control mice were subjected to induced OA
by DMM surgery. Consistent with our data from the total
KO mice, Lrp5fl/fl;Col2a1-cre mice exhibited significantly
reduced cartilage destruction following DMM surgeryFigure 5 Catabolic regulation of LRP5 mediates via β-catenin-Tcf/Lef
(EV) or pSPORT6-Lrp5 plus the TOPflash or FOPflash reporter constructs. After
luciferase reporter gene assays (n = 7 independent experiments). (B) Chondro
1 ng/ml interleukin 1β (IL-1β), 50 ng/ml Wnt3a or 500 ng/ml Wnt7a, and tran
gene assays (n = 6). Values are expressed as means ± SEM (*P < 0.005). (C) β-c
destabilization of the medial meniscus (DMM) surgery were determined by im
staining was used for visualization of nuclei. Scale bar: 20 μm. (D) β-catenin, m
undamaged (Normal) and damaged (osteoarthritis; OA) human osteoarthritic
MMP3 and MMP13 expression levels in spontaneous (aging-induced) osteoar
mice and their WT littermates were examined by immunohistochemistry. Scacompared with control Lrp5fl/fl mice (Figure 6B) and did
not show DMM surgery–induced upregulation of β-
catenin, MMP3 and MMP13 expression levels in OA cartil-
age samples (Figure 6C). We also examined whether the
upregulation of LRP5 could potentiate chondrocyte apop-
tosis and found that chondrocyte apoptosis induced by
1 μg/ml anti-Fas antibody was not altered by Lrp5 defi-
ciency (Figure 6D). However, stimulation of apoptosis by
IL-1β treatment in the presence of a low concentration
(0.1 μg/ml) of anti-Fas antibody was slightly but signifi-
cantly reduced in Lrp5-deficient chondrocytes (Figure 6D).
As determined by TUNEL assay, apoptotic cells were also
relatively reduced in DMM-induced OA cartilage from
Lrp5fl/fl;Col2a1-cre mice compared to Lrp5fl/fl mice
(Figure 6E). Taken together, our results suggest that LRP5
induces chondrocyte dedifferentiation and promotes thesignaling. (A) Chondrocytes were transfected with 1 μg of empty vector
24 hours, transcriptional activation by β-catenin was determined by
cytes obtained from wild-type (WT) and Lrp5−/− mice were treated with
scriptional activation by β-catenin was evaluated by luciferase reporter
atenin and LRP5 expression levels in cartilage after sham operation or
munofluorescence microscopy. 4′,6-diamidino-2-phenylindole (DAPI)
atrix metalloproteinase 3 (MMP3) and MMP13 expression levels in
cartilage were examined by immunostaining. (E) and (F) β-catenin,
thritic cartilage and DMM-induced osteoarthritic cartilage from Lrp5−/−




Figure 6 Suppression of β-catenin and matrix metalloproteinase expression levels in chondrocyte-specific Lrp5-knockout mice.
(A) Col2a1-Cre-transgenic mice were backcrossed with Lrp5fl/fl mice to generate Lrp5fl/fl;Col2a1-Cre mice. RT-PCR was used to examine deletion of
the Lrp5 gene in cartilage versus brain, heart and bone. WT: Wild type. (B) Cartilage destruction in Lrp5fl/fl;Col2a1-cre and control LRP5fl/fl mice
subjected to sham operations and destabilization of the medial meniscus (DMM) surgery was evaluated by Safranin O staining and Mankin score
(n = 15 independent experimental animals). Scale bar: 50 μm. (C) The expression levels of LRP5, β-catenin, matrix metalloproteinase 3 (MMP3) and
MMP13 in sham-operated control cartilage and DMM-operated osteoarthritic cartilage of LRP5fl/fl;Col2a1-cre and LRP5fl/fl mice were determined by
immunohistochemical staining. Scale bar: 50 μm. (D) Primary cultures of articular chondrocytes isolated from WT and Lrp5−/− mice were treated
with the indicated amounts of anti-Fas antibody for 6 hours or treated with 1 ng/ml IL-1β for 24 hours and with 0.1 μg/ml of anti-Fas antibody
for an additional 6 hours. Apoptotic cells were quantified by fluorescence-activated cell sorting analysis (n = 5), Con: Control; IgG: Immunoglobulin
G. (E) Apoptotic chondrocytes were visualized by 4′,6-diamidino-2-phenylindole (DAPI) staining and terminal deoxynucleotidyl transferase deoxyuridine
triphosphate nick end labeling (TUNEL) assays of cartilage samples from Lrp5fl/fl;Col2a1-cre and control LRP5fl/fl mice after sham operations and DMM
surgery. Values are expressed as means ± SEM (*P < 0.05, **P < 0.001). Scale bar: 50 μm.
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MMP3 and MMP13) by potentiating the Wnt/β-catenin
signaling pathway.Discussion
Disturbance of cartilage homeostasis is a main cause of
OA pathogenesis. In OA, cartilage destruction is
Shin et al. Arthritis Research & Therapy 2014, 16:R37 Page 10 of 12
http://arthritis-research.com/content/16/1/R37initiated by defects in joint biomechanics in conjunction
with predisposing factors (for example, age, genetics and
various systemic aspects), leading to an imbalance of
anabolic and catabolic factors [2]. Various biochemical
pathways are modulated, resulting in the insufficient
synthesis of cartilage matrix by chondrocytes, increased
numbers of apoptotic chondrocytes [27] and degradation
of the ECM due to increased production of MMPs and
ADAMTS [2,3]. In this study, we demonstrate that Lrp5
is a crucial catabolic regulator of Wnt/β-catenin sig-
naling–mediated OA cartilage destruction. We first ob-
served upregulation of LRP5 in human and experimental
mouse OA cartilage samples. Our evaluation of the spe-
cific functions of LRP5 in OA pathogenesis further re-
vealed that Lrp5 deficiency in mice (Lrp5−/−) exerted a
protective effect against OA pathogenesis. Our results
additionally suggest that the catabolic regulation of
LRP5 is associated with its capacity to initiate Wnt-
mediated expression of catabolic factors, such as MMP3
and MMP13, and decrease the anabolic factor, type II
collagen.
LRP5 and LRP6 are paralogs that are 70% identical,
and both are capable of stimulating the Wnt/β-catenin
signaling pathway. Even though they have redundant
and overlapping functions [28,29], several previous re-
ports have suggested that LRP5 and LRP6 also play dis-
tinct roles due to their differences in tissue distribution
and ligand affinities [11,30]. For example, a loss-of-
function mutation in Lrp5 causes OPPG syndrome, a
disorder involving low bone mass [12], whereas Lrp6 de-
ficiency (Lrp6−/−) in mice is an embryonic lethal disorder
[14], and a heterozygous loss-of-function mutation in
Lrp6 (Lrp6+/−) is associated with decreased β-catenin
signaling within articular cartilage and increased degen-
erative joint disease after ligament and meniscus injury
[31]. These previous findings indicate that the specific re-
ceptors for LRP5 and LRP6 control different functions,
presumably by interacting with distinct ligands of the Wnt
family. In an effort to further confirm the catabolic regula-
tion of Lrp5, we examined the expression levels of Lrp5
and Lrp6 in differentiating chondrocytes, human OA car-
tilage and cartilage samples from various experimental
mouse models of OA. We observed distinct expression
patterns for Lrp5 and Lrp6 during chondrogenesis and the
IL-1β-induced dedifferentiation of chondrocytes. LRP5 ex-
pression in OA cartilage was increased, consistent with
previous reports [15,16], whereas LRP6 expression was
unaltered. These findings provide additional evidence that
LRP5 and LRP6 have distinct expression patterns and may
play different roles in OA cartilage destruction.
Previous studies have suggested that LRP5 may con-
tribute to OA pathogenesis, but its function in OA carti-
lage destruction has been the subject of some controversy.
LRP5 expression was found to be significantly upregulatedin human OA cartilage [16], and a cohort study suggested
that haplotypes of the Lrp5 gene are risk factors for
OA [15]. Conversely, however, mild instability-induced
OA in Lrp5−/− mice was reportedly associated with
increased cartilage degradation [18]. Our data are incon-
sistent with the latter observation, even though the two
studies seem consistent in terms of the method used to
induce OA (DMM surgery), the duration after surgery
(8 weeks) and the utilized mouse strain (C57BL6/J). To
examine whether whole-body Lrp5 deficiency could affect
gene expression in other tissues by altering the sus-
ceptibility to pathogenic stimulation, we examined the
chondrocyte-specific in vivo function of LRP5 in condi-
tional KO mice (Lrp5fl/fl;Col2a1-cre) to exclude any unex-
pected side effects from the loss of Lrp5 in other tissues.
However, we found that the inhibitory effect of Lrp5 defi-
ciency on DMM surgery–induced OA cartilage de-
gradation in Lrp5fl/fl;Col2a1-cre mice was consistent with
the results from total Lrp5−/− mice. These data indicate
that LRP5 has catabolic effects during OA cartilage
degradation.
In the current study, we used recombinant Wnt3a and
Wnt7a as representative ligands of the canonical Wnt/
β-catenin signaling pathway to evaluate the function of
Lrp5. We did not examine the upregulation of Wnt
molecules in the OA cartilage of our experimental sys-
tems, but Wnt3a is known to activate the canonical Wnt
pathway and stimulate the expression of Mmp13 and
Adamts4 in mouse chondrocytes [32,33]. We previously
showed that IL-1β upregulates Wnt7a expression,
thereby inhibiting type II collagen expression in chon-
drocytes [34]. Moreover, we found that the expression
levels of various Wnt and Fz receptor isotypes were reg-
ulated by IL-1β [4]. In this study, we found that stimula-
tion of canonical Wnt signaling via Wnt3a treatment
caused upregulation of Mmp13 in mouse articular chon-
drocytes, whereas Wnt7a treatment decreased Col2a1
expression and increased Mmp3 and Mmp13 expression.
Our observation that Wnt7a and IL-1β have similar
effects on gene expression in chondrocytes is consistent
with a previous report [4] in which we showed that
IL-1β induced upregulation of Wnt7a in articular chon-
drocytes. Notably, however, the Wnt-mediated regulation
of Col2a1, Mmp3 and Mmp13 were abrogated in primary
cultured chondrocytes from Lrp5−/− mice. On the basis of
these data, we speculate that catabolic gene expression is
convergently modulated by IL-1β in chondrocytes, with
IL-1β-mediated Wnt7a and Lrp5 expression triggering
downregulation of Col2a1 and upregulation of Mmp3 and
Mmp13, potentially contributing to the IL-1β-induced
activation of β-catenin.
The catabolic effects of LRP5 may be attributable to its
capacity to upregulate Mmp3 and Mmp13, which encode
proteins that are capable of degrading a variety of ECM
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genetic studies in mice have clearly demonstrated that
MMP3 and MMP13 play crucial roles in OA pathogenesis
[36,37]. We observed that Wnt3a induced the expression
of Adamts4 (data not shown). Notably, however, Adamts4
deficiency in mice did not show protective effects against
OA cartilage destruction [38], whereas Mmp13-KO mice
are resistant to OA cartilage erosion [37]. Therefore, the
capacity of LRP5 to facilitate the Wnt-induced expression
of MMP13 (a common catabolic factor that is regulated
by both Wnt3a and Wnt7a) appears to be associated with
the positive effects of LRP5 on OA cartilage destruction.
The LRP5-induced downregulation of the anabolic factor
type II collagen (a marker protein of chondrocytes) in
articular chondrocytes also contributes to cartilage de-
struction. We found that ectopic expression of LRP5
induced the dedifferentiation of chondrocytes and was
associated with the pathogenesis of OA. The apoptosis of
chondrocytes, which is associated with the pathogenesis
of OA, can be induced by a number of stimuli [39,40]. As
we previously showed that Fas and its ligand are phy-
siologically involved in chondrocyte apoptosis [41], in our
present study we used an anti-Fas antibody to evaluate the
role of LRP5 in chondrocyte apoptosis. The decreased
chondrocyte apoptosis in Lrp5fl/fl;Col2a1-cre mice sub-
jected to DMM surgery supports our contention that
LRP5 plays a catabolic role in OA cartilage destruction.Conclusions
Herein we provide evidence suggesting that LRP5 is a
catabolic regulator of OA pathogenesis and report that
IL-1β treatment increases LRP5 expression largely via
JNK and NF-κB signaling. On the basis of our results,
we suggest that LRP5 plays a catabolic role in OA
cartilage destruction by decreasing type II collagen syn-
thesis (thus facilitating chondrocyte dedifferentiation),
increasing MMP3 and/or MMP13 expression and pro-
moting chondrocyte apoptosis. These results provide
new insight into the mechanisms by which LRP5 upreg-
ulation contributes to OA cartilage and suggest that
LRP5 could be a candidate therapeutic target for new
strategies to treat or prevent OA.Abbreviations
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